A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer.

Trial Profile

A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Fosaprepitant (Primary) ; Aprepitant
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov
    • 09 Mar 2015 Status changed from recruiting to discontinued, as reported by the ClinicalTrials.gov.
    • 24 Jan 2014 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top